MLYS
NASDAQMineralys Therapeutics Inc.
News25/Ratings11
News · 26 weeks84+75%
2026-04-192026-10-11
Mix3990d
- SEC Filings15(38%)
- Other11(28%)
- Insider10(26%)
- Earnings1(3%)
- Offering1(3%)
- Analyst1(3%)
Latest news
25 items- SECSEC Form 144 filed by Mineralys Therapeutics Inc.144 - Mineralys Therapeutics, Inc. (0001933414) (Subject)
- ANALYSTUBS initiated coverage on Mineralys Therapeutics with a new price targetUBS initiated coverage of Mineralys Therapeutics with a rating of Neutral and set a new price target of $29.00
- PRMineralys Therapeutics Presents New Data for Lorundrostat at the American Heart Association Hypertension Scientific Sessions 2026- New analyses from the pivotal Launch-HTN trial showed that 46% of participants with difficult-to-treat hypertension receiving lorundrostat 50 mg achieved the AHA/ACC Guideline systolic blood pressure target of <130 mmHg at 12 weeks, with more than two-thirds achieving ≥10 mmHg systolic blood pressure reduction - - In the Explore-OSA trial in participants with obstructive sleep apnea, lorundrostat 50 mg taken once daily in the evening achieved clinically meaningful reductions in morning systolic blood pressure with no measurable change in apnea-hypopnea indices - RADNOR, Pa., Oct. 09, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a biopharmaceutical company focuse
- INSIDERChief Executive Officer Congleton Jon sold $1,909,665 worth of shares (75,000 units at $25.46) as part of a pre-agreed trading plan, decreasing direct ownership by 12% to 528,621 units (SEC Form 4)4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)
- PRMineralys Therapeutics Announces Presentation of New Lorundrostat Data at the American Society of Nephrology (ASN) Kidney Week 2026RADNOR, Pa., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone, today announced that new data from the Launch-HTN trial of lorundrostat will be presented at the American Society of Nephrology Kidney Week 2026, taking place October 21-25 in Denver, Colorado. Oral Presentation Details: Title:Blood Pressure and Albuminuria Reduction with Lorundrostat in Chronic Kidney Disease Stages 1 to 3 in the Launch-HTN tria
- PRMineralys Therapeutics Announces Presentation of Lorundrostat Data at American Heart Association Hypertension Scientific Sessions 2026RADNOR, Pa., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced that five abstracts will be presented at the American Heart Association (AHA) Hypertension Scientific Sessions 2026, taking place October 7-11 in Arlington, VA. Oral Presentation Details: Title:Efficacy and Safety of the Selective Aldosterone Synthase Inhibitor Lorundrostat in Moderate-to-Severe Obstructive Sleep Apnea and H
- SECSEC Form 144 filed by Mineralys Therapeutics Inc.144 - Mineralys Therapeutics, Inc. (0001933414) (Subject)
- PRMineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)RADNOR, Pa., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone, announced today that, on September 28, 2026, the Compensation Committee of Mineralys’ Board of Directors granted inducement stock option awards covering an aggregate of 46,430 shares and inducement restricted stock unit awards covering an aggregate of 34,823 shares of Mineralys common stock to two new non-executive employees. The awards were gra
- INSIDERDirector Slingsby Brian Taylor sold $3,005,303 worth of shares (104,320 units at $28.81) (SEC Form 4)4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)
- PRMineralys Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic ForumRADNOR, Pa., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone, announced today that management will be participating in the Stifel 2026 Virtual Cardiometabolic Forum taking place on September 30, 2026. Stifel 2026 Virtual Cardiometabolic ForumDate: Wednesday, September 30, 2026Time: 12:00pm ETFormat: Fireside Chat A live webcast of this fireside chat can be accessed on the "News & Events" page in the Inves
- INSIDERChief Commercial Officer Warren Eric exercised 7,438 shares at a strike of $13.24 and sold $209,136 worth of shares (7,438 units at $28.12) as part of a pre-agreed trading plan (SEC Form 4)4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)
- SECSEC Form 144 filed by Mineralys Therapeutics Inc.144 - Mineralys Therapeutics, Inc. (0001933414) (Subject)
- SECSEC Form 144 filed by Mineralys Therapeutics Inc.144 - Mineralys Therapeutics, Inc. (0001933414) (Subject)
- PRMineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)RADNOR, Pa., Sept. 21, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone, announced today that, on September 21, 2026, the Compensation Committee of Mineralys’ Board of Directors granted an inducement stock option award covering 14,880 shares and an inducement restricted stock unit award covering 11,160 shares of Mineralys common stock to a new non-executive employee. The awards were granted under Mineralys’ 2025 Empl
- INSIDERDirector Karydas Daphne exercised 3,000 shares at a strike of $12.02 and sold $85,740 worth of shares (3,000 units at $28.58) as part of a pre-agreed trading plan (SEC Form 4)4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)
- SECSEC Form 144 filed by Mineralys Therapeutics Inc.144 - Mineralys Therapeutics, Inc. (0001933414) (Subject)
- SECSEC Form 144 filed by Mineralys Therapeutics Inc.144 - Mineralys Therapeutics, Inc. (0001933414) (Subject)
- SECSEC Form 144 filed by Mineralys Therapeutics Inc.144 - Mineralys Therapeutics, Inc. (0001933414) (Subject)
- SECSEC Form 144 filed by Mineralys Therapeutics Inc.144 - Mineralys Therapeutics, Inc. (0001933414) (Subject)
- PRMineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)RADNOR, Pa., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone, announced today that, on September 8, 2026, the Compensation Committee of Mineralys’ Board of Directors granted inducement stock option awards covering an aggregate of 29,760 shares and inducement restricted stock unit awards covering an aggregate of 22,320 shares of Mineralys common stock to two new non-executive employees. The awards were gran
- PRMineralys Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare ConferenceRADNOR, Pa., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone, announced today that management will be participating in the Wells Fargo 21st Annual Healthcare Conference being held in Boston on September 8-10, 2026. Wells Fargo 21st Annual Healthcare ConferenceDate:Wednesday, September 9, 2026Time:4:30pm EDTFormat:Fireside ChatWebcast Link:Click Here A live webcast of this fireside chat can also be accessed
- INSIDERChief Commercial Officer Warren Eric exercised 7,437 shares at a strike of $13.24 and sold $193,189 worth of shares (7,437 units at $25.98) as part of a pre-agreed trading plan (SEC Form 4)4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)
- SECSEC Form 144 filed by Mineralys Therapeutics Inc.144 - Mineralys Therapeutics, Inc. (0001933414) (Subject)
- SECSEC Form 144 filed by Mineralys Therapeutics Inc.144 - Mineralys Therapeutics, Inc. (0001933414) (Subject)
- SECSEC Form 144 filed by Mineralys Therapeutics Inc.144 - Mineralys Therapeutics, Inc. (0001933414) (Subject)
MLYS FAQ
6 questionsWhere does MLYS stock trade?
Mineralys Therapeutics Inc. (MLYS) is listed on NASDAQ.What sector and industry is MLYS in?
Mineralys Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Mineralys Therapeutics Inc. go public?
Mineralys Therapeutics Inc. (MLYS) completed its IPO in 2023.What are analysts saying about MLYS?
Mineralys Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from UBS: Neutral with a $2900.00 price target on 2026-10-12. Recent price targets range from $1500.00 to $3900.00.What companies are similar to MLYS?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare MLYS side-by-side with any of them on Quantisnow.How can I track MLYS on Quantisnow?
Quantisnow aggregates Mineralys Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MLYS to receive live email and push alerts on every new disclosure.